

Table 1: Proportion of patients in each health state after year 1 and 2 from the DRCRNet Trial.

Parameter	Year 1	Year 2
Laser		
≥ 20/25	0.20 (0.15 - 0.25)	0.21 (0.16 - 0.26)
20/32-20/40	0.3 (0.25 - 0.35)	0.36 (0.31 - 0.41)
20/50-20/63	0.25 (0.2 - 0.3)	0.18 (0.14 - 0.22)
20/80-20/100	0.11 (0.07 - 0.15)	0.10 (0.07 - 0.13)
20/125-20/160	0.08 (0.05 - 0.11)	0.04 (0.02 - 0.06)
≤ 20/200	0.06 (0.03 - 0.09)	0.10 (0.07 - 0.13)
Ranibizumab+Laser*		
≥ 20/25	0.34 (0.27 - 0.41)	0.37 (0.3 - 0.44)
20/32-20/40	0.37 (0.3 - 0.44)	0.31 (0.24 - 0.38)
20/50-20/63	0.14 (0.09 - 0.19)	0.11 (0.07 - 0.15)
20/80-20/100	0.06 (0.03 - 0.09)	0.08 (0.04 - 0.12)
20/125-20/160	0.04 (0.01 - 0.07)	0.1 (0.06 - 0.14)
≤ 20/200	0.04 (0.01 - 0.07)	0.03 (0.01 - 0.05)
Ranibizumab+Delayed Laser*		
≥ 20/25	0.35 (0.28 - 0.42)	0.32 (0.25 - 0.39)
20/32-20/40	0.35 (0.28 - 0.42)	0.38 (0.31 - 0.45)
20/50-20/63	0.18 (0.13 - 0.23)	0.2 (0.14 - 0.26)
20/80-20/100	0.09 (0.05 - 0.13)	0.06 (0.03 - 0.09)
20/125-20/160	0.02 (0 - 0.04)	0.01 (0 - 0.02)
≤ 20/200	0.02 (0 - 0.04)	0.04 (0.01 - 0.07)
Triamcinolone+Laser		
≥ 20/25	0.22 (0.16 - 0.28)	0.29 (0.22 - 0.36)
20/32-20/40	0.3 (0.23 - 0.37)	0.25 (0.19 - 0.31)
20/50-20/63	0.23 (0.17 - 0.29)	0.13 (0.08 - 0.18)
20/80-20/100	0.15 (0.1 - 0.2)	0.18 (0.12 - 0.24)
20/125-20/160	0.08 (0.04 - 0.12)	0.05 (0.02 - 0.08)
≤ 20/200	0.03 (0.01 - 0.05)	0.1 (0.06 - 0.14)

*For analyses with bevacizumab, we assumed equal efficacy to ranibizumab.